Table 3.
Summary and comparison of vital signs among the treatments.
| Vital Sign | Timepoint of Measurement (1) | ||||
|---|---|---|---|---|---|
| Screening (n = 36) |
Tamsulosin Alone (T1) (n = 35) |
Mirabegron Alone (T2) (n = 34) |
Tamsulosin + Mirabegron (T3) (n = 34) |
p-Value (2) | |
| SBP (mmHg) | 128.97 (12.04) | 119.23 (8.92) | 120.56 (9.56) | 117.18 (8.72) | 0.3058 |
| DBP (mmHg) | 78.78 (8.25) | 76.26 (9.71) | 73.76 (6.77) | 75.29 (8.61) | 0.4708 |
| HR (bpm) | 77.08 (9.47) | 64.97 (9.28) | 67.97 (8.82) | 67.00 (8.32) | 0.5490 |
| Change from the Screening in each treatment | |||||
| SBP (mmHg) | - | −10.57 (12.99) | −9.06 (11.22) | −12.44 (12.24) | 0.5120 |
| DBP (mmHg) | - | −2.83 (10.34) | −5.06 (7.65) | −3.53 (10.84) | 0.6243 |
| HR (bpm) | - | −12.26 (10.84) | −12.44 (11.27) | −10.41 (10.07) | 0.6898 |
(1) Measured at 0 h (pre-dose) in the steady state of each period: day 5 in tamsulosin alone (T1), day 19 in mirabegron alone (T2), and day 26 in the combination (T3). (2) The differences among the 3 treatments were compared using one-way analysis of variance. Data from the screening were excluded from the statistical analysis. Data are presented as mean (standard deviation). DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure.